This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.



Eligible Ages
Over 12 Years
Eligible Genders
Accepts Healthy Volunteers

Inclusion Criteria

  • Hospitalized with COVID-19 pneumonia confirmed per a positive polymerase chain reaction (PCR) of any specimen (e.g., respiratory, blood, urine, stool, other bodily fluid) and evidenced by chest X-ray or CT scan - Requiring more than 6 L/min supplemental oxygen to maintain SpO2 > 93% - Agrees to not participate in another clinical trial for the treatment of COVID-19 while participating in this study

Exclusion Criteria

  • Known severe allergic reactions to tocilizumab or other monoclonal antibodies - Known hypersensitivity to remdesivir, the metabolites, or formulation excipients - Active tuberculosis (TB) infection - Suspected active bacterial, fungal, viral, or other infection (besides COVID-19) - In the opinion of the investigator, progression to death is imminent and inevitable within the next 24 hours, irrespective of the provision of treatments - Treatment with immunosuppressive or immunomodulatory therapy (including tocilizumab) within the past 3 months - Concurrent treatment with other agents with actual or possible direct-acting antiviral activity against SARS-CoV-2 within 24 hours prior to study drug dosing. In addition, participants with prior or current treatment with > 2 doses of remdesivir for COVID-19 are excluded - Participating in other drug clinical trials - Estimated glomerular filtration rate (eGFR) < 30 mL/min (including patients receiving hemodialysis or hemofiltration) - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 5 x upper limit of normal (ULN) detected within 24 hours of screening (according to local laboratory reference ranges) - Absolute neutrophil count (ANC) < 1000/uL at screening - Platelet count < 50,000/uL at screening - Body weight < 40 kg - Treatment with an investigational drug within 5 half-lives or 30 days (whichever is longer) of randomization

Study Design

Phase 3
Study Type
Intervention Model
Parallel Assignment
Primary Purpose
Double (Participant, Investigator)

Arm Groups

ArmDescriptionAssigned Intervention
Remdesivir + Tocilizumab (RDV+TCZ)
Participants assigned to the RDV+TCZ arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ on Day 1.
  • Drug: Remdesivir
    Participants will receive intravenous (IV) RDV
  • Drug: Tocilizumab
    Participants will receive IV TCZ
Active Comparator
Remdesivir + Placebo (RDV+Placebo)
Participants assigned to the RDV+ placebo arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ-placebo on Day 1.
  • Drug: Remdesivir
    Participants will receive intravenous (IV) RDV
  • Drug: Placebo
    Participants will receive IV placebo matched to TCZ

Recruiting Locations

Boston Medical Center
Boston, Massachusetts 02118-2393

More Details

Hoffmann-La Roche

Study Contact

Reference Study ID #: WA42511 www.roche.com/about_roche/roche_worldwide.htm


Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.